Categories
Change Password!
Reset Password!
This prospective single-center, randomized superiority controlled clinical focused on evaluating the efficacy of two protocols- doxycycline-based quadruple regimen and levofloxacin concomitant regimen as empirical first-line therapy for the treatment of Helicobacter pylori (H. pylori) infected patients.
This trial supported the use of both concomitant and
bismuth-containing quadruple therapies as substitute first-line therapy for H.
pylori-infected individuals as per earlier guidelines, especially in areas with
a high incidence of clarithromycin resistance.
This prospective
single-center, randomized superiority controlled clinical focused on evaluating
the efficacy of two protocols- doxycycline-based quadruple regimen and
levofloxacin concomitant regimen as empirical first-line therapy for the
treatment of Helicobacter pylori (H. pylori) infected patients.
Seventy-eight naïve patients
infected with H. pylori were included, and these patients were stratified into
two groups based on therapies given twice daily for 2 weeks:
After eight weeks of therapy, a stool antigen
test was used to confirm the H. pylori elimination.
The number of participants who completed the follow-up and were cured is shown in Table 1:
The eradication rates as per intention-to-treat and per-protocol analyses are shown in Table 2:
No serious adverse effects
were reported.
Levofloxacin therapy did
not show superiority to doxycycline quadruple therapy. However, future research
can help to find out the ideal first-line therapy for H. pylori.
BMC Infectious Diseases
Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial
Marouf Alhalabi et al.
Comments (0)